Retrospective Study Comparing Niraparib Versus Bevacizumab as Maintenance Therapy After Platinum-based Chemotherapy in Patients With High-grade Stage III and IV Ovarian Cancer Without Homologous Recombination Deficiency

What this Trial Is About

This research aims to compare two maintenance treatments, bevacizumab and niraparib, in patients with advanced high-grade serous epithelial ovarian carcinoma (stage III and IV) who do not have certain biomolecular abnormalities like BRCA mutations or high HRD scores. The study focuses on progression-free survival and overall survival to help understand which treatment might be more appropriate for this patient group. It is a retrospective, observational study using medical records from patients treated between October 2020 and December 2023. Patients included in the study have received first-line platinum-based chemotherapy followed by maintenance therapy with either bevacizumab or niraparib. The study groups consist of patients who received niraparib monotherapy or bevacizumab monotherapy as maintenance treatment after chemotherapy. Data collection is retrospective, based on electronic case report forms from multiple centers. The study excludes patients with disease progression after chemotherapy or those with BRCA mutations or positive HRD scores. Participants' medical records are reviewed to collect clinical, biological, and sociodemographic data. The primary outcome is progression-free survival from the start of maintenance therapy until disease progression or death, assessed up to 38 months. Secondary outcomes include overall survival within the same timeframe. This study does not involve active treatment or visits but relies on existing data to analyze treatment outcomes and patient characteristics over time.

Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency